Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
PACB Stock Forecast 2026-2027
$1.31
Current Price
$406.89M
Market Cap
Buy 4
Hold 2
Sell 1
Wall St Analyst Ratings
Distance to PACB Price Targets
+129.0%
To High Target of $3.00
+100.4%
To Median Target of $2.63
+14.5%
To Low Target of $1.50
PACB Price Momentum
-9.7%
1 Week Change
+8.3%
1 Month Change
+9.2%
1 Year Change
-29.9%
Year-to-Date Change
-52.0%
From 52W High of $2.73
+20.2%
From 52W Low of $1.09
📊 TOP ANALYST CALLS
Did PACB Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if PACB is one of their latest high-conviction picks.
Latest PACB Stock Price Targets & Analyst Predictions
Based on our analysis of 2 Wall Street analysts, PACB has a bullish consensus with a median price target of $2.63 (ranging from $1.50 to $3.00). The overall analyst rating is Strong Buy (8.0/10). Currently trading at $1.31, the median forecast implies a 100.4% upside. This outlook is supported by 4 Buy, 2 Hold, and 1 Sell ratings.
Conversely, the most conservative target is provided by Luke Sergott at Barclays, suggesting a 14.5% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
PACB Analyst Ratings
4
Buy
2
Hold
1
Sell
PACB Price Target Range
Low
$1.50
Average
$2.63
High
$3.00
Current: $1.31
Latest PACB Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for PACB.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 11, 2026 | Barclays | Luke Sergott | Underweight | Maintains | $1.50 |
| Apr 14, 2026 | Barclays | Underweight | Maintains | $N/A | |
| Mar 6, 2026 | Barclays | Underweight | Downgrade | $N/A | |
| Dec 15, 2025 | Barclays | Equal-Weight | Maintains | $N/A | |
| Nov 11, 2025 | Piper Sandler | Neutral | Maintains | $N/A | |
| Nov 10, 2025 | Stephens & Co. | Overweight | Maintains | $N/A | |
| Aug 11, 2025 | Piper Sandler | Neutral | Maintains | $N/A | |
| Jun 25, 2025 | Barclays | Equal-Weight | Maintains | $N/A | |
| May 15, 2025 | Piper Sandler | Neutral | Maintains | $N/A | |
| May 15, 2025 | Stephens & Co. | Overweight | Reiterates | $N/A | |
| Apr 10, 2025 | Canaccord Genuity | Buy | Maintains | $N/A | |
| Mar 25, 2025 | Scotiabank | Sector Outperform | Maintains | $N/A | |
| Feb 20, 2025 | Piper Sandler | Neutral | Reiterates | $N/A | |
| Feb 18, 2025 | Goldman Sachs | Neutral | Maintains | $N/A | |
| Feb 18, 2025 | Stephens & Co. | Overweight | Reiterates | $N/A | |
| Feb 14, 2025 | Stephens & Co. | Overweight | Reiterates | $N/A | |
| Jan 23, 2025 | Goldman Sachs | Neutral | Maintains | $N/A | |
| Nov 11, 2024 | UBS | Neutral | Downgrade | $N/A | |
| Nov 11, 2024 | Scotiabank | Sector Outperform | Maintains | $N/A | |
| Nov 11, 2024 | Piper Sandler | Neutral | Maintains | $N/A |
Pacific Biosciences of California, Inc. (PACB) Competitors
The following stocks are similar to PACB based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
PACB
Pacific Biosciences
mkt cap
406.89M
Pacific Biosciences of California, Inc. (PACB) Financial Data
Pacific Biosciences of California, Inc. has a market capitalization of $406.89M with a P/E ratio of -0.7x. The company generates $160.03M in trailing twelve-month revenue with a -80.3% profit margin.
Revenue growth is +0.1% quarter-over-quarter, while maintaining an operating margin of -102.9% and return on equity of -273.6%.
Valuation Metrics
Market Cap
$406.89M
Enterprise Value
$855.95M
P/E Ratio
-0.7x
PEG Ratio
0.0x
Price/Sales
2.6x
Growth & Margins
Revenue Growth (YoY)
+0.1%
Gross Margin
+34.5%
Operating Margin
-102.9%
Net Margin
-80.3%
EPS Growth
+0.1%
Financial Health
Cash/Price Ratio
+67.8%
Current Ratio
5.7x
Debt/Equity
29,855.8x
ROE
-273.6%
ROA
-12.0%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Pacific Biosciences of California, Inc. (PACB) Business Model
About Pacific Biosciences of California, Inc.
What They Do
Develops advanced DNA sequencing systems.
Business Model
The company employs a razor-and-blade business model, generating revenue through the sale of sequencing instruments and recurring sales of consumables needed for those instruments. This approach ensures a continuous revenue stream as customers frequently purchase consumables after acquiring the initial equipment.
Additional Information
Founded in 2004 and based in Menlo Park, California, the company caters to a diverse clientele, including academic institutions, pharmaceutical companies, and agricultural organizations. Their technologies are crucial for applications in human genetics, oncology, and various genomics fields.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
485
CEO
Mr. Christian O. Henry M.B.A.
Country
United States
IPO Year
2010
Website
www.pacb.comPacific Biosciences of California, Inc. (PACB) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Pacific Biosciences of California (PACB) Stock Sinks As Market Gains: Here's Why
Pacific Biosciences of California (PACB) closed the most recent trading day at $1.31, moving 2.96% from the previous trading session.
Jun 12, 2026
By Zacks Equity Research
Tale of the Tape
Here's Why You Should Retain Glaukos Stock in Your Portfolio Now
Glaukos is riding strong on iDose TR growth and launching Epioxa into a large underpenetrated market, but reimbursement and competition risks persist.
Jun 05, 2026
By Zacks Equity Research
Analyst Blog
Here's Why You Should Add PacBio Stock to Your Portfolio Now
PACB's growth is supported by HiFi sequencing advances and product momentum, though funding pressures weigh on instrument demand.
Jun 03, 2026
By Zacks Equity Research
Analyst Blog
Latest News
Quick Summary
Pacific Biosciences of California (PACB) closed at $1.31, reflecting a 2.96% increase from the previous trading session.
Why It Matters
PACB's recent price movement indicates volatility, which may signal investor sentiment and potential trading opportunities. Changes in stock price can impact market perception and future investments.
Source: Zacks Investment Research
Market Sentiment:
Negative
Quick Summary
PACB's growth is driven by HiFi sequencing advancements and strong product momentum, but funding pressures are negatively impacting instrument demand.
Why It Matters
PACB's growth from HiFi sequencing could indicate strong future revenue, but funding pressures may hinder instrument sales, affecting overall profitability and stock performance.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Genomics and synthetic biology are driving healthcare innovation, increasing interest in precision medicine and boosting stocks such as PACB, MYGN, and TWST.
Why It Matters
Rising demand for precision medicine boosts interest in genomics and synthetic biology stocks, indicating potential growth opportunities and market shifts for investors.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
PACB has launched the SPRQ-Nx for Revio, enhancing HiFi sequencing with AI and epigenetics features while reducing costs by approximately 30%.
Why It Matters
PACB's cost reduction and technological upgrades in sequencing enhance its competitive edge, potentially increasing market share and revenue, which can positively impact stock performance.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
New Revio multi-use SMRT Cells lower sequencing costs by 30% and enhance accuracy, yield, and epigenetic insights with improvements in DeepConsensus and methylation calling.
Why It Matters
Lower sequencing costs and enhanced accuracy can boost demand for Revio's technology, potentially increasing market share and profitability for the company.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
PacBio (NASDAQ: PACB) will participate in a fireside chat at the Jefferies' Global Healthcare Conference on June 4, 2026, at 2:00 PM ET in New York.
Why It Matters
PacBio's participation in a prominent healthcare conference signals engagement with investors and potential market insights, which may influence stock performance and investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About PACB Stock
What is Pacific Biosciences of California, Inc.'s (PACB) stock forecast for 2026?
Based on our analysis of 2 Wall Street analysts, Pacific Biosciences of California, Inc. (PACB) has a median price target of $2.63. The highest price target is $3.00 and the lowest is $1.50.
Is PACB stock a good investment in 2026?
According to current analyst ratings, PACB has 4 Buy ratings, 2 Hold ratings, and 1 Sell ratings. The stock is currently trading at $1.31. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for PACB stock?
Wall Street analysts predict PACB stock could reach $2.63 in the next 12 months. This represents a 100.4% increase from the current price of $1.31. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Pacific Biosciences of California, Inc.'s business model?
The company employs a razor-and-blade business model, generating revenue through the sale of sequencing instruments and recurring sales of consumables needed for those instruments. This approach ensures a continuous revenue stream as customers frequently purchase consumables after acquiring the initial equipment.
What is the highest forecasted price for PACB Pacific Biosciences of California, Inc.?
The highest price target for PACB is $3.00 from at , which represents a 129.0% increase from the current price of $1.31.
What is the lowest forecasted price for PACB Pacific Biosciences of California, Inc.?
The lowest price target for PACB is $1.50 from Luke Sergott at Barclays, which represents a 14.5% increase from the current price of $1.31.
What is the overall PACB consensus from analysts for Pacific Biosciences of California, Inc.?
The overall analyst consensus for PACB is bullish. Out of 2 Wall Street analysts, 4 rate it as Buy, 2 as Hold, and 1 as Sell, with a median price target of $2.63.
How accurate are PACB stock price projections?
Stock price projections, including those for Pacific Biosciences of California, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 14, 2026 1:42 AM UTC